Hana Pharm Co., Ltd. (293480.KS)
KRW 11260.0
(0.18%)
KRW 11260.0
(0.18%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 26.53 Billion KRW | -22.19% |
| 2022 | 34.09 Billion KRW | 216.48% |
| 2021 | 10.77 Billion KRW | 139.49% |
| 2020 | 4.49 Billion KRW | -17.52% |
| 2019 | 5.45 Billion KRW | 17.33% |
| 2018 | 4.64 Billion KRW | -83.99% |
| 2017 | 29.04 Billion KRW | -6.1% |
| 2016 | 30.93 Billion KRW | -11.98% |
| 2015 | 35.14 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 33.52 Billion KRW | 34.78% |
| 2024 Q1 | 24.87 Billion KRW | -6.25% |
| 2023 Q2 | 29.72 Billion KRW | 9.17% |
| 2023 Q1 | 27.22 Billion KRW | -20.16% |
| 2023 FY | 26.53 Billion KRW | -22.19% |
| 2023 Q4 | 26.53 Billion KRW | -11.84% |
| 2023 Q3 | 30.09 Billion KRW | 1.27% |
| 2022 Q1 | 34.15 Billion KRW | 216.99% |
| 2022 FY | 34.09 Billion KRW | 216.48% |
| 2022 Q4 | 34.09 Billion KRW | -2.44% |
| 2022 Q3 | 34.95 Billion KRW | 5.5% |
| 2022 Q2 | 33.13 Billion KRW | -3.0% |
| 2021 Q3 | 4.14 Billion KRW | -0.88% |
| 2021 Q4 | 10.77 Billion KRW | 159.93% |
| 2021 FY | 10.77 Billion KRW | 139.49% |
| 2021 Q1 | 4.21 Billion KRW | -6.25% |
| 2021 Q2 | 4.18 Billion KRW | -0.85% |
| 2020 Q3 | 4.85 Billion KRW | 2.06% |
| 2020 Q4 | 4.49 Billion KRW | -7.28% |
| 2020 FY | 4.49 Billion KRW | -17.52% |
| 2020 Q1 | 5.12 Billion KRW | -6.12% |
| 2020 Q2 | 4.75 Billion KRW | -7.16% |
| 2019 Q4 | 5.45 Billion KRW | -66.07% |
| 2019 FY | 5.45 Billion KRW | 17.33% |
| 2019 Q3 | 16.07 Billion KRW | 5.1% |
| 2019 Q1 | 5.56 Billion KRW | 19.75% |
| 2019 Q2 | 15.29 Billion KRW | 174.74% |
| 2018 FY | 4.64 Billion KRW | -83.99% |
| 2018 Q3 | 18.8 Billion KRW | -12.22% |
| 2018 Q4 | 4.64 Billion KRW | -75.28% |
| 2018 Q2 | 21.42 Billion KRW | 0.0% |
| 2017 FY | 29.04 Billion KRW | -6.1% |
| 2016 FY | 30.93 Billion KRW | -11.98% |
| 2015 FY | 35.14 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 60.329% |
| Yuhan Corporation | 230.07 Billion KRW | 88.467% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 32.669% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 93.055% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 96.165% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 84.418% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 84.418% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 94.331% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | 38.684% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 84.666% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | 13.466% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 85.341% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 81.833% |
| Boryung Corporation | 204.21 Billion KRW | 87.007% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 68.843% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 88.74% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -1955.983% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -4098.1% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 70.676% |
| CKD Bio Corp. | 146.92 Billion KRW | 81.941% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 88.21% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 87.927% |
| Yuhan Corporation | 230.07 Billion KRW | 88.467% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 42.509% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 32.669% |
| HANDOK Inc. | 300.01 Billion KRW | 91.156% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 93.476% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 95.368% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -4355.701% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 94.329% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 77.635% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 32.669% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -11042.448% |
| JW Holdings Corporation | 554.58 Billion KRW | 95.216% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 87.82% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 84.418% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | 32.322% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 84.914% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 68.772% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 94.351% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 42.509% |
| Korea United Pharm Inc. | 40.33 Billion KRW | 34.225% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | 45.015% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 66.578% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 68.843% |
| JW Lifescience Corporation | 46.31 Billion KRW | 42.709% |